Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bayer to acquire Schiff Nutrition International for US$1.2 billion, adding MegaRed, Move Free and Airborne brands to bolster its U.S. consumer-health and OTC…
Schiff's go-shop clause enabled the alternative bid; Reckitt's superior offer prevailed, leaving Bayer without the targeted US VMS platform — a clear setback…
C&EN reported that Reckitt Benckiser's $42/share, $1.4B bid topped Bayer's $34/share October agreement; Bayer declined to match and exited, with Reckitt…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Bayer HealthCare announced $34/share cash deal for Schiff Nutrition (~$1.2B). Schiff FY2012 net sales $259M. Bayer was subsequently outbid by Reckitt Benckiser at $42/share ($1.4B); Bayer declined to raise. Note: nutraceutical/consumer-health, included as borderline pharma carve-out of major pharma activity.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Schiff Nutrition International, Inc. (this deal) | 2012 | $1.2B | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2012 deals · Bayer AG deals · Other deals